Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results

Oculis (NASDAQ:OCS) released its quarterly earnings results on Tuesday. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28), Zacks reports. Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Oculis Price Performance

OCS opened at $18.84 on Thursday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $763.10 million, a P/E ratio of -9.76 and a beta of 0.02. The stock has a 50-day moving average price of $20.86 and a 200-day moving average price of $16.88. Oculis has a 12-month low of $10.55 and a 12-month high of $23.08.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on OCS shares. Chardan Capital restated a “buy” rating and issued a $28.00 target price on shares of Oculis in a research note on Thursday. Robert W. Baird upped their price objective on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, HC Wainwright dropped their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.